OpenEvidence, an artificial intelligence platform designed to help doctors quickly find and interpret medical research, has raised $250 million in a Series D funding round, pushing the company’s valuation to $12 billion—more than double its valuation just months ago.
The round was co-led by Thrive Capital and DST Global, with participation from major technology and healthcare investors including Sequoia Capital, Google Ventures, Nvidia, Kleiner Perkins, and the Mayo Clinic. With this latest raise, OpenEvidence’s total funding now stands at nearly $700 million since its launch.
Founded in 2022 by Daniel Nadler and Zachary Ziegler, OpenEvidence has become widely known among clinicians as a “brain extender” for doctors. The platform uses specialised AI models to synthesise answers from peer-reviewed medical journals, clinical guidelines, and trusted scientific sources, helping physicians make faster, evidence-based decisions at the point of care.
According to the company, OpenEvidence supported approximately 18 million clinical consultations in December 2025 alone, a dramatic rise from roughly three million monthly consultations a year earlier. The platform is now used by more than 40 percent of U.S. physicians, across over 10,000 hospitals and medical institutions.
“If a doctor tried to stay current by reading all new evidence published in leading medical journals, it would take their entire day,” said CEO Daniel Nadler. “Our goal is to give clinicians instant access to the most relevant, up-to-date evidence when it matters most.”
OpenEvidence remains free for verified physicians, generating revenue through advertising and partnerships rather than subscriptions. The company estimates that in 2025 alone, over 100 million Americans were treated by clinicians using its AI-powered tools, highlighting the platform’s growing influence on everyday healthcare delivery.
The newly raised capital will be used to expand OpenEvidence’s computing infrastructure, improve its specialised AI models, and accelerate research and development. The company is also focused on deepening its clinical accuracy by routing medical queries to sub-specialty AI systems tailored to specific fields such as cardiology, oncology, and emergency medicine.
Industry analysts view OpenEvidence’s rapid growth as a strong signal that domain-specific AI tools—particularly in healthcare—are becoming one of the most valuable applications of generative AI, where speed, accuracy, and trust can directly impact patient outcomes.
